Laurence Cooper

Ziopharm Oncology Inc. (NASDAQ: ZIOP) has two goals. One is to disrupt the narrative around recurrent glioblastomas. The other is to disrupt the entire pharmaceutical supply chain. The latter pursuit isn’t just a B2B revenue opportunity, it's meant to alleviate cost barriers to critical...

• ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) CEO Dr. Laurence Cooper believes that the company’s cell programming languages set it apart from other cancer researchers. • The company’s Sleeping Beauty platform allows for T cell modification without the use of a viral...